Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | +14.60% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.31 | N/A | +14.60% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding their product pipeline. They acknowledged the challenges but emphasized their commitment to innovation.
Management highlighted ongoing progress in their pipeline.
They expressed confidence in future developments despite current challenges.
Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 4.8% following the earnings report, likely due to a lack of revenue information and no updated guidance. Investors may be concerned about the company's future performance without clearer direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Oct 31, 2011